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Bioengineered bone substitutes might represent alternatives to autologous bone grafts in medically compromised patients due
to reduced operation time and comorbidity. Due to the lack of an inherent vascular system their dimension is limited to
the size of critical bone size defect. To overcome this shortcoming, the experiment tried to create heterotopic bone around
vessels. In vivo, a two-component fibrin and thrombin gel containing recombinant bone morphogenic protein (rhBMP-2) and
transglutamate vascular endothelial growth factor (TG-VEGF) in different ratios, respectively, was injected into a dimensionally
stable membrane tube, wrapped around the femoral vessel bundle in twelve New Zealand white rabbits. Sacrifice occurred
eight weeks postoperatively. Microcomputed tomography of the specimens showed significantly increased bone volume in the
rhBMP-2 to TG-VEGF ratio of 10 to 1 group. Histology showed new bone formation in close proximity to the vessel bundle.
Immunohistochemistry detected increased angiogenesis within the newly formed bone in the rhBMP-2 to TG-VEGF ratios of
3 to 1 and 5 to 1. Heterotopic bone was engineered in vivo around vessels using different rhBMP-2 and TG-VEGF ratios in a fibrin
matrix injected into a dimensionally stable membrane tube which prevented direct contact with skeletal muscles.
1. Introduction
Bone substitutes created by tissue engineering provide novel
options in the treatment strategy of large bone defects [1].
As engineered bone grafts usually lack inherent vascular
systems, promotion of angiogenesis becomes fundamental
for their survival once in situ [2]. A way to overcome
the shortcoming of lacking inherent vascular system in
engineered bone could be engineering bone around vessels.
Recently, in vivo heterotopic bone formation was detected
around vessels within a preformed dimensionally stable
membrane tube, filled up with a fibrin gel matrix containing
bone morphogenetic protein-2 (rhBMP-2) [3].
After heterotopic bone formation around vessels has
been detected when administering rhBMP-2 only in different
dosages, it became of interest to investigate eventual angio-
genesis within this bone, adding vascular endothelial growth
factor (VEGF) in different ratios to rhBMP-2. The VEGF
family is of utmost importance to induce angiogenesis during
bone formation [4]. So far, their interactionwith BMP related
to bone formation has been widely investigated in animals
[5–11]. While endothelial cells modulate osteoprogenitor cell
differentiation through a BMP-2 signaling pathway during
bone healing [12], endothelial cell proliferation is stimu-
lated by VEGF producing osteoblasts [13]. This interaction,
depending on specific BMP to VEGF ratios, was detected
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in animal models investigating critical bone size defects or
ectopic bone formation under direct contact with skeletal
muscles; BMP to VEGF ratios in those studies varied widely
between 50 : 1 and 1 : 5 [5, 9–11]. The ideal ratio to achieve
maximum bone regeneration, however, has not yet been
found [5].
TG-VEGF, developed in 2001 [14], was used in this
experiment due to its efficient covalent incorporation into
fibrin which permits a slow, continuous release and because
of its scientifically proven durable promotion in neovessel
formation due to its continuous angiogenic signal [15, 16].
The present study investigated heterotopic bone forma-
tion with concomitant angiogenesis around vessels promoted
by rhBMP-2 to TG-VEGF ratios of 10 : 1, 5 : 1, and 3 : 1,
respectively [5, 9–11], in a fibrin matrix, separated from
contact with skeletal muscles by a membrane.
2. Materials and Methods
2.1. Preparation of Tisseel Lyo Containing the Growth Factors.
The preparations of the rhBMP-2 and TG-VEGF used in this
study have already been described [14, 17, 18]. 125 𝜇g rhBMP-
2 (original concentration 1𝜇g/𝜇L), considered to be the
ideal dosage for heterotopic bone formation in a previously
performed animal pilot study [3], was diluted in 125𝜇L Tris-
HCl (1mM) solution. The rhBMP-2 solution was supple-
mented with 50 𝜇L thrombin (Tisseel Lyo, Baxter, Vienna,
Austria) to ultimately obtain 300 𝜇L solution. Three different
dosages of TG-VEGFweremixed with fibrinogen, the second
component of Tisseel Lyo (Baxter, Vienna, Austria), to create
a 75 𝜇L solution. This solution was then diluted in 225𝜇L
Tris-buffered saline (TBS). The fibrinogen and thrombin
solutions, each 300 𝜇L, were charged in two different car-
tridges. These cartridges were mounted into a Duploject
syringe (Baxter, Vienna, Austria). On injection, formation
of fibrin gel started due to the mixing of both substances
within the needle. The process was accomplished in situ once
injection around the vessels within the Inion guided tissue
regeneration (GTR) membrane tube was completed.
2.2. Animal Model. The study was approved by the Commit-
tee on the Use of Live Animals for Teaching and Research
(CULATR no. 1637-08), The University of Hong Kong, Hong
Kong.
Twelve New Zealand white rabbits (3.0 to 4.2 kg), 6 to 9
months old, were used in this animal trial. The rabbits were
allocated into 4 groups (𝑛 = 3 per group). The dosage of
rhBMP-2 (125 𝜇g) was maintained for all groups. In Group A,
only rhBMP-2 (125 𝜇g) was administered. This group served
as control group. Groups B, C, and D received different
rhBMP-2 to TG-VEGF ratios: 10 to 1 (125 𝜇g to 12.5 𝜇g), 5 to 1
(125 𝜇g to 25𝜇g), and 3 to 1 (41.7 𝜇g to 12.5 𝜇g), respectively.
All surgical procedures were performed in the Lab-
oratory Animal Unit (LAU) of The University of Hong
Kong. Preoperatively 30mg/kg of long-acting oxytetracycline
(Troy Laboratories Pty Limited, Glendenning, Australia)
and 30 𝜇g/kg Temgesic (Reckitt Benckiser Health, Slough,
UK) were administered. All animals were anesthetized by
an experienced veterinarian via injection into the gluteal
muscle using a mixture of acepromazine (1mg/kg; Delvet Pty
Ltd., Asquith, Australia), ketamine (45mg/kg; Alfasan Inter-
national B.V., Woerden, Holland), and xylazine (5mg/kg;
Alfasan International B.V., Woerden, Holland). The rabbits
were put in a supine position with the right knee joint in
flexion. A face mask continually delivered 1.5–2% Forane
(Halocarbon Laboratories, River Edge, NJ, USA) to maintain
adequate anaesthetic depth during the surgery. The animal
model in this study corresponds step by step to the one
the authors have established and described in detail already
elsewhere [3]. In brief, an Inion guided tissue regeneration
(GTR) membrane sheet (Inion Oy, Tampere, Finland) was
formed into a 1 cm long tube. This tube was wrapped around
the femoral vessel bundle and secured in place with two
Vicryl 4/0 (Johnson & Johnson, Hong Kong) sutures. After
the cylinders were filled up with fibrin gel containing growth
factors in various ratios as mentioned above, wound closure
was performed in layers with Vicryl 4/0 and Ethilon 5/0
(Johnson & Johnson, Hong Kong) in single suture technique.
Postoperative care was performed in collaboration with
veterinarians. Drugs used for postoperative care included
long-acting oxytetracycline (30mg/kg; Troy Laboratories
Pty Limited, Glendenning, Australia), buprenorphine
(0.05mg/kg; Reckitt Benckiser Health, Slough, United
Kingdom), andmeloxicam (0.2mg/kg;Metacam, Boehringer
Ingelheim, Ingelheim, Germany).
2.3. Specimen Harvest. Eight weeks postoperatively the ani-
mals were sacrificed using pentobarbital sodium (150mg/kg;
Alfasan International B.V., Woerden, Holland). The Inion
GTR tubes were dissected together with a surrounding
soft tissue pad. Specimens were immersed in 10% neutral
formalin solution for histopathological and microcomputed
tomography analyses.
2.4. Microcomputed Tomography. Each specimen was
scanned and reconstructed by amicrocomputed tomography
machine (SkyScan 1076; Bruker, Kontich, Belgium) with a
0.5mm aluminum filter, at a voltage of 59 kV, using a current
of 149 𝜇A. New bone formation within the Inion GTR cylin-
ders was studied by analyzing serial micro-CT images of the
specimen at a 12 𝜇mpixel resolution.The reconstruction data
was assessed with CTAnalyzer version 1.9 software (SkyScan,
Kontich, Belgium).The region of interest (ROI) was specified
as the area of bone tissue within the specimen. Bone volume
data of the ROI was extracted to perform statistical analysis.
2.5. Histologic Examination. The specimens were decalcified
in 12.5% ethylenediaminetetraacetic acid (EDTA) for about
2 weeks at a pH 7.2 (Sigma, New York, NY, USA) and room
temperature. The solution was changed daily. To avoid any
eventual skeletal muscle effect on bone formation at both
tube ends, each specimen was cut into three equally sized
parts, from which only the middle part was processed for
sectioning. Subsequently specimens were dehydrated with
graded series of ethanol and embedded in paraffin. With
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Figure 1: At ×1 magnification, four areas (1–4) were demarcated
around the femoral vessel bundle by applying tangents to its borders.
Microvessel density in the resulting four areas was counted at ×20
magnification.
a microtome (Leica RM2155; Leica Biosystems, Nussloch,
Germany), five sections, each 6 𝜇m in thickness, were cut
in five equally sized pieces of the middle part. All tissue
sections were stained with hematoxylin/eosin (H&E) (Sigma,
NY, USA; Merck, NJ, USA, resp.) and investigated visually
as well as photographed under a light microscope (Leica
DMLB), at both ×2 and ×10 magnifications.
2.6. Immunohistochemical Staining. Endothelial cell adhe-
sionmolecule-1 (CD31) (Abcam, Cambridge, UK), being able
to recognize the rabbit-specific signals [19, 20], served as pri-
mary antibody to detect microvessels. Tissue sections (6 𝜇m)
were deparaffinized in sequential xylene and rehydrated in
graded alcohol baths. Sections were rinsed with phosphate
buffered saline (PBS, PH 7.4, 0.1M) (Advanced Technology &
Industrial Co., Hong Kong). Antigen retrieval was performed
in 0.1% trypsin solution at 37∘C for 60 minutes according to
manufacturer’s instruction. To quench endogenous peroxi-
dase activity, the sections were incubated in freshly prepared
0.3% hydrogen peroxide for 30 minutes. After rinsing in
phosphate buffered saline (PBS) for 3 times, the sections
were blocked with 1.5% normal goat serum for 60 minutes
at 37∘C. Thereafter they were rinsed again three times with
PBS and incubated overnight in primary mouse antibodies
against rabbit CD31 (Abcam, Cambridge, UK) at a dilution of
1 : 20 at 4∘C. Subsequently the sections were incubated with
anti-mouse immunoglobulin G antibody followed by avidin
and biotin reagents for 60minutes. Diaminobenzidine (DAB,
Santa Cruz Biotechnology, Dallas, TX, USA) was used to
detect eventual reaction. Finally the sections were then rinsed
in deionized water for 5 minutes and counterstained with
hematoxylin.
Figure 2: 3D micro-CT reconstruction of the newly formed bone
within the membrane tube from Group D.
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Figure 3: Bone volume amount of the four different groups.
2.7. Microvessel Density (MVD) Evaluation. After being
mounted in a xylene-based medium (VWR International,
Radnor, PA, USA), the sections were examined under a light
microscope (Leica DMLB; Leica Biosystems, Nussloch, Ger-
many). Microvessel density (MVD) was evaluated according
to the guidelines already published elsewhere [21–23]. Posi-
tive staining of a single endothelial cell or cluster of endothe-
lial cells was defined as microvessel. Vessels with muscular
wall were excluded. The targeted area was defined according
to our protocol published previously [20]. Four areas around
the femoral vein were determined at ×1 magnification under
microscope as indicated in Figure 1. Microvessels in the
center of these areas were observed at higher magnification
(×20) and counted by a blinded investigator. Mean MVD of
these three histological fields was considered as the ultimate
evaluation of MVD (microvessel/mm2) in one section.
2.8. Statistical Analysis. Meanbone volume andMVDamong
different groups were compared statistically using one-way
ANOVA(SPSS version 20, Chicago, IL,USA).TheBonferroni
test was used to conduct multiple comparison between each
two groups. A 𝑃 ≤ 0.05 was considered to be statistically
significant.
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Figure 4: Group A rhBMP-2 alone (a), Group B rhBMP-2 : VEGF = 10 : 1 (b), Group C rhBMP-2 : VEGF = 5 : 1 (c), and Group D rhBMP-
2 : VEGF = 3 : 1 (d). Mature bone tissue (arrows) is well visible adjacent to the femoral vessel bundle (∗) in Group A (a) and Group B (b).
3. Results
All animals underwent an uneventful postoperative recovery
phase. No adverse events occurred until the time of sacrifice.
Two weeks after the operation all animals regained both pre-
operative nutritional intake and their normal daily activities.
Suture removal was performed two weeks postoperatively in
all animals, disclosing normal wound healing.
3.1. Micro-CT. Serial imaging detected newly formed bone
tissue in all specimens. 3D reconstruction visualized new
bone formation around the vessels (Figure 2). The bone
volume in Group B (rhBMP to VEGF is 10 to 1) was
significantly increased compared to Groups D (rhBMP to
VEGF is 3 to 1) (𝑃 = 0.005) and C (rhBMP to VEGF is 5
to 1) (𝑃 = 0.006; Figure 3). Even though quantitatively more
bone was found in Group B compared to Group A (rhBMP-
2 alone), the difference was not statistically significant (𝑃 >
0.05; Figure 3).
3.2. Histologic Examination. Histology reiterated micro-CT
findings in terms of newly formed bone tissue in Group D
(Figure 4(d)). Most bone tissue was found in proximity to the
femoral vessel bundle. Hardly any bone formation was found
in Group B and Group C (Figures 4(b) and 4(c)). No bone
tissue could be detected near the Inion GTR membrane.
3.3. Immunohistochemical Staining. Immunohistochemical
staining with anti-CD31 antibody visualized clusters of vas-
cular endothelial cells around the femoral vessel bundle
(Figures 5(a) to 5(d)). MVD in Group A, Group B, Group
C, and Group D was 72.2 ± 3.3, 77.5 ± 8.1, 88.5 ± 5.9,
and 85.4 ± 8.5, vessels/mm2, respectively. No statistically
significant difference among Groups B, C, and D was found
regarding MVD.
4. Discussion
Deprived of direct skeletal muscle contact, heterotopic bone
formation around vessels was detected to be best promoted
using the rhBMP-2 to TG-VEGF ratio of 10 to 1. Further
on, rhBMP-2 to TG-VEGF ratios of 3 to 1 and 5 to 1, both,
increased microvascular density within the newly formed
bone.
Interactions of different members of the BMP and VEGF
families related to bone development have been investigated
in various animal models [5–11, 24]. Many studies [5–10]
stated a synergistic or additive effect of both growth factors.
However, as mentioned by Young et al., 2009, the ideal ratio
of BMP toVEGF depends on particular animalmodels, study
duration, delivery matrixes, and assessment methods [11].
In this study continuous release of growth factors occurred
from the fibrin gel being in direct contact to vessels, however,
separated from surrounding skeletal muscles by amembrane.
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Figure 5: Group A rhBMP-2 alone (a), Group B rhBMP-2 : VEGF = 10 : 1 (b), Group C rhBMP-2 : VEGF = 5 : 1 (c), and Group D rhBMP-
2 : VEGF = 3 : 1 (d). Arrows point at microvessels. MVD in groups with both growth factors ((b), (c), and (d)) was increased compared to the
group with rhBMP-2 only (a).
Only the rhBMP-2 to TG-VEGF ratio of 10 to 1 seemed to
promote heterotopic bone formation. Further on, the bone
volume at low rhBMP-2 to TG-VEGF ratios was less than in
the group with rhBMP-2 alone, a finding which is in line with
the results of Peng et al. in 2005 and 2002 [9, 10]. They found
impaired bone formation in decreased BMP to VEGF ratios
and concluded that increased proportions of VEGF probably
led mesenchymal stem cells to differentiate into endothelial
rather than osteogenic cells. A similar finding was revealed
in this study, where increased MVD was detected in groups
with decreased rhBMP-2 to TG-VEGF ratios.
TG-VEGF contains an additional factor XIIIa substrate
sequence. It was developed in 2001 by Zisch et al. [14]. Its
highly efficient covalent incorporation into fibrin, preventing
its rapid clearance and allowing an increased vessel induction
effect compared to thewild typeVEGF,was confirmed in vitro
[15]. Since 2008, its durable promotion in neovessel formation
due to the release of a continuous angiogenic signal has been
approved scientifically [16].
The Inion GTR membrane tube provided two distinct
functions: (1) it prevented direct contact between the fibrin
matrix loaded with the growth factors and the surrounding
skeletal muscles, and (2) it served as a scaffold for the fibrin
gel, as it became dimensionally stable when hardened. This
dimensional stability of the tube provided the basis for the
steady release of rhBMP-2 and TG-VEGF from the fibrin gel,
probably resulting in the formation of bone andmicrovessels.
Today’s CAD/CAM technique allows for the generation
of custom made 3D anatomically identical bone pieces out
of different materials for immediate bone substitution. Load
bearing biodegradable material might become a real alter-
native in bone reconstructive procedures. They could be of
help to reduce operation time and therefore the comorbidity
due to autologous microvascular composite grafts, especially
in medically compromised patients. Ideally biodegradable
material should be substituted by in-growing bone from the
contact zones between material and local bone. In larger
than critical bone size defects, however, it is still debated
whether this process occurs late or not at all in the center of
bone grafts. The here presented heterotopic bone formation
around vessels possibly could represent a method to over-
come this problem. What if a biodegradable, load bearing
material could be used as a gouged scaffold where a close-
by dissected or mobilized vessel bundle could be laid inside
and covered with fibrin gel containing the above-mentioned
growth factors? Heterotopic bone engineering around vessels
is an interesting concept to further investigate.
The following critical shortcomings need to be pointed
out. First, MVD among the groups with various rhBMP-2
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and TG-VEGF ratios turned out not to be of statistical sig-
nificance, similar as the amount of bone generation between
Groups A and D. This lack of significance originates most
probably from the small animal number. Second, to exclude
preexistent vessels in the specimen, vessels with a muscle
layer were not counted when assessing the MVD. As sacrifice
occurred in the postoperative week eight, some TG-VEGF
elicited, but alreadymoremature vessels thereforemight have
been left out of being counted, biasing the end result.
Third, to fill the InionGTRmembrane tubewith the fibrin
gel emerged as a technical shortcoming. A temporary hand
glove drain had to be used to close one end of the tube during
the filling procedure, a somewhat difficult and imprecise task.
Future research with this animal model and larger sample
sizes should focus on the investigation of biodegradable and
load bearing scaffolds, such as boron hardened bioglass.With
thismaterial sacrificemight be performed at 12 weeks or later,
a time span not feasible for the here used membrane with
its degradation time of 8 weeks. Further on, investigations
related to bone formation with angiogenesis should target
rhBMP-2 to TG-VEGF ratios between 5 to 1 and 10 to 1.
5. Conclusions
Heterotopic bone was created around vessels without direct
contact to skeletal muscle. Synergistic effect of rhBMP-2
and TG-VEGF related to bone formation depended on their
particular ratios.Whereas a ratio of 10 to 1 turned out to be in
favor for bone formation, angiogenesis was promoted using
ratios of 3 to 1 and 5 to 1, respectively.
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